OXIS INTERNATIONAL, INC. |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| May. 20 | Top Premarket Gainers | MT |
| Mar. 26 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 10.77M |
|---|---|---|---|---|---|
| Net income 2024 * | -17M | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.72
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.13% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 62 | 21-01-12 |
Manu Ohri
DFI | Director of Finance/CFO | 67 | 22-02-17 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 22-12-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 23-04-30 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 20-11-10 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 21-01-12 |
GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system.
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
2024-06-25
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +37.58% | 705B | |
| +32.43% | 583B | |
| -2.88% | 364B | |
| +20.73% | 332B | |
| +5.90% | 291B | |
| +16.34% | 238B | |
| -3.48% | 210B | |
| +10.56% | 209B | |
| +9.40% | 169B |
